Securities code: Beihai Gofar Chuanshan Biological Co.Ltd(600538) securities abbreviation: Beihai Gofar Chuanshan Biological Co.Ltd(600538) Announcement No.: pro 2022019
Beihai Guofa Chuanshan Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd
Announcement on correction of 2020 Annual Report
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
1、 Reasons for correction of 2020 Annual Report
From August to September 2021, Guangxi Securities Regulatory Bureau conducted on-site inspection on Beihai Guofa Chuanshan Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd. (hereinafter referred to as "the company"), and issued the letter of regulatory concern on Relevant Issues of Beihai Guofa Chuanshan Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd. (GJH [2021] No. 755) at the end of 2021. The company attached great importance to the problems found in the on-site inspection and actively carried out rectification, mainly to correct and retroactively adjust the errors in the 2020 financial statements of the holding subsidiary Goldman Sachs Biotechnology Co., Ltd. (hereinafter referred to as "Goldman Sachs biotechnology"), and then correct and retroactively adjust the accounting errors in the 2020 consolidated financial statements of the company. 2、 Impact of 2020 annual report correction on the company
On March 25, 2022, the company held the 16th meeting of the 10th board of directors and the 13th meeting of the 10th board of supervisors, deliberated and adopted the proposal on correction and retroactive adjustment of accounting errors in the early stage, and made error correction and retroactive adjustment to the company's 2020 financial statements. The impact on the company's financial statements in 2020 is as follows:
1. After correcting and retroactively adjusting the accounting errors in the financial statements of Goldman Sachs biology in 2020, the operating income in 2020 was increased by 1377500 yuan and the net profit attributable to the parent company was increased by 666700 yuan. 2. Since the equity transfer procedures for the company's acquisition of Goldman Sachs biology were completed at the end of December 2020, the company's 2020 annual report did not include Goldman Sachs biology's 2020 profit and cash flow. The above error correction items only affect the company's consolidated balance sheet on December 31, 2020, and have no impact on the company's consolidated income statement and consolidated cash flow statement in 2020.
For details, see Shanghai Securities News, securities times, Securities Daily, China Securities News and the website of Shanghai Stock Exchange on March 29, 2022（ http://www.sse.com.cn. ）Announcement on correction and retroactive adjustment of major accounting errors in the previous period disclosed.
3、 Specific contents of correction in 2020 Annual Report
According to the above errors and retroactive adjustments, the full text of the company's 2020 annual report is corrected. The main contents of the correction are as follows:
(I) for "section II Company Profile and main financial indicators" - "VII. Main accounting in recent three years"
Correction of main accounting data in "data and financial indicators".
(II) "analysis of assets and liabilities" in "section IV discussion and analysis of operation"
Make corrections.
(III) highlight "analysis of major holding and participating companies" in "section IV discussion and analysis of business conditions"
The business analysis content of Shengsheng biology is corrected as follows:
The audited net profit attributable to the shareholders of the parent company of Goldman Sachs biology in 2020 was 286023 million yuan,
After deducting non recurring profits and losses, the net profit attributable to the shareholders of the parent company was RMB 240283 million, which completed the business of the current year
105.85% of the performance commitment (after deducting non recurring profits and losses in 2020 promised by kangxiantong and other counterparties)
The net profit is 22.7 million yuan). Goldman Sachs biology is a subsidiary of the company through reorganization and acquisition in this period, and its equity is too large
The accounting procedures were completed at the end of December 2020, and the company did not include its income statement in the scope of consolidated statements in the current period.
(IV) "balance sheet" and "changes in consolidated owner's equity" in "section Xi financial report"
The relevant items in the "table" are corrected as follows:
Unit: Yuan
After the correction of the item, the amount is corrected.
Accounts receivable 17806833885 -16525497017641578915
Inventory 5839180999 -841396475755041352
Other current assets 628733738 -12510672616223066
Goodwill 25476272989 -6666845225409604537
Deferred income tax assets 27 Welle Environmental Group Co.Ltd(300190) 5614 Ningbo Runhe High-Tech Materials Co.Ltd(300727) 9144912
Total assets 106893749981 -322430734106571319247
Contract liabilities 3099622248 -2916938682807928380
Taxes payable 1084164126 - 25106141081653512
Other current liabilities 508365931 -17501632490864299
Total liabilities 21726596349 -31170611421414890235
Minority shareholders' equity 725430938 -10724620714706318
Total owner's equity 85167153632 -1072462085156429012
Total liabilities and owner's equity 106893749981 -322430734106571319247
(V) correct the accounts receivable, inventories, other current assets, goodwill, deferred income tax assets / deferred income tax liabilities, contract liabilities, taxes payable, other current liabilities and other relevant contents in "v. important accounting policies and accounting estimates" in section Xi financial report.
(VI) correct the business combination and segment information not under the same control in "VIII. Change of consolidation scope" in section Xi financial report.
The full text of the company's 2020 annual report (Revised Version) is detailed on the website of Shanghai Stock Exchange on March 29, 2022 (www.sse. Com. CN.). The contents marked in red in the full text of 2020 annual report (Revised Version) are the information corrected in the annual report.
The Company Apologizes for the inconvenience caused to investors by the correction of the annual report.
It is hereby announced.
Board of directors of Beihai Guofa Chuanshan Jinyu Bio-Technology Co.Ltd(600201) Co., Ltd
March 29, 2022
